Saturday, July 23, 2022 10:00:35 AM
Hard to tell exactly what is going on with Zander since we have not had any fins for 2 1/2 years, however I am not sure how they are getting .186168 per share?
NOTE 9. INVESTMENT SECURITIES, RELATED PARY
On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics, Inc.
On November 29, 2018 the Company accepted 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. in satisfaction of prepaid rent and accrued interest owed to the Company collectively amounting to $13,124.
On June 30,2022 the Company revalued 470,588 of the common shares of Zander Therapeutics, Inc. and 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs:
Fair Value of Intellectual Property $ 1,500
Prepaid Expenses 65,661
Due from Employee 1,071
Note Receivable 64,400
Accrued Interest Receivable 23,989
Investment Securities 8,423,366
Convertible Note Receivable 10,000
Accounts Payable 1,269,041
Notes Payable 400,000
Accrued Expenses Related Parties 162,011
Notes Payable Related Party 5396
Accrued Expenses 203,037
Enterprise Value 10,563,930
Less: Total Debt (2,038,343 )
Portion of Enterprise Value Attributable to Shareholders 8,525,587
Fair Value Per Share $ 0.186168
The abovementioned constitute the Company’s sole related party investment securities as of June 30, 2022
As of June 30, 2022:
470,588 Common Shares of Zander Therapeutics, Inc.
Basis Fair Value Total Unrealized
Gains Net Unrealized Gain or (Loss) realized during the quarter ended June 30,2022
$ 5,741 $ 87,608 $ 81,867 $ 79,749
725,000 Series M Preferred of Zander Therapeutics, Inc.
Basis Fair Value Total Unrealized Gain Net Unrealized Gain or (Loss) realized during the quarter ended June 30, 2022
$ $13,124 $ 134,971 $ 121,847 $ 122,861
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM